S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005833|
Recruitment Status : Completed
First Posted : April 12, 2004
Last Update Posted : June 14, 2012
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or advanced colorectal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: R115777||Phase 2|
OBJECTIVES: I. Determine the response rate to R115777 in patients with disseminated colorectal cancer who have been previously treated for advanced disease. II. Assess the time to treatment failure and survival of these patients with this treatment regimen. III. Determine the frequency and severity of toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive oral R115777 twice daily on days 1-21. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 2 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 5-7 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Colorectal Cancer|
|Study Start Date :||June 2000|
|Actual Primary Completion Date :||July 2006|
|Actual Study Completion Date :||July 2006|
R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
300mg P.O. BID.
Other Name: NSC-702818
- Confirmed complete and partial response rate to R115777 [ Time Frame: Once every 8 weeks until progression ]Confirmed complete and partial response rate to R115777 in pts with measurable, disseminated colorectal cancer and no prior therapy for advanced disease.
- Time to treatment failure and survival [ Time Frame: Once every 8 weeks until progression, then once every 6 months for 2 years, then annually until 3 years from registration ]To assess time to treatment failure and survival in this group of patients.
- Frequency & severity of toxicities [ Time Frame: Weekly for 8 weeks and then once every 4 weeks until progression ]To assess the frequency and severity of toxicities associated with this treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005833
|United States, California|
|USC/Norris Comprehensive Cancer Center|
|Los Angeles, California, United States, 90033-0800|
|Veterans Affairs Outpatient Clinic - Martinez|
|Martinez, California, United States, 94553|
|University of California Davis Medical Center|
|Sacramento, California, United States, 95817|
|United States, Illinois|
|CCOP - Central Illinois|
|Decatur, Illinois, United States, 62526|
|United States, Kansas|
|CCOP - Wichita|
|Wichita, Kansas, United States, 67214-3882|
|Veterans Affairs Medical Center - Wichita|
|Wichita, Kansas, United States, 67218|
|United States, Missouri|
|CCOP - Kansas City|
|Kansas City, Missouri, United States, 64131|
|United States, Montana|
|CCOP - Montana Cancer Consortium|
|Billings, Montana, United States, 59101|
|United States, Ohio|
|CCOP - Columbus|
|Columbus, Ohio, United States, 43206|
|United States, South Carolina|
|CCOP - Greenville|
|Greenville, South Carolina, United States, 29615|
|CCOP - Upstate Carolina|
|Spartanburg, South Carolina, United States, 29303|
|United States, Washington|
|CCOP - Northwest|
|Tacoma, Washington, United States, 98405-0986|
|Study Chair:||Robert P. Whitehead, MD||University of Texas|